PA Student Psychiatry Rotation Course & PAEA EOR Prep

Overview of the SMU Psychiatry Rotation Guide

Welcome to your comprehensive clinical curriculum and board preparation guide, engineered specifically for clinical-year Physician Assistant (PA) students at Samuel Merritt University. This resource is tailored to help you excel on your psychiatric rotation, impress your preceptors, and successfully master the PAEA Psychiatric & Behavioral Health End of Rotation (EOR) exam blueprint.

To ensure your success both on the wards and during your 120-question computerized exam, this curriculum is divided into two clinical pillars:

1. Rotation & Clinical Skills: Your practical toolkit for navigating the psychiatric floor, covering the psychiatric interview, the Mental Status Exam (MSE), 3-minute oral case presentations, psychiatric SOAP notes, acute agitation de-escalation, and involuntary commitment legal criteria.

2. High-Yield Clinical Pathology: Standardized, board-style profiles of DSM-5-TR conditions complete with diagnostic criteria, look-alikes, multi-line psychopharmacological regimens, and high-yield clinical vignettes.

Part 1: Rotation & Clinical Skills

When performing a psychiatric assessment, you must adapt your general medical interview skills to emphasize patient safety, historical collateral, and behavioral observations. Because psychiatric patients may sometimes present with acute distress or altered sensorium, your communication style must pivot from structured interrogation to therapeutic, active listening.

The Psychiatric Interview & History

Your history-taking should systematically explore the Chief Complaint (CC), History of Present Illness (HPI), Past Psychiatric History (including previous hospitalizations, suicide attempts, and outpatient therapies), Substance Use History, and Social History.

The Mental Status Exam (MSE)

Your preceptors at Samuel Merritt University will expect you to present the MSE using a standardized clinical sequence:

• Appearance & Behavior: Grooming, hygiene, cooperative vs. guarded attitude, eye contact.
• Motor Activity: Psychomotor agitation (e.g., hand-wringing) vs. psychomotor retardation (e.g., slowed movements), tremors, or abnormal posturing.
• Speech: Rate, volume, articulation, and latency.
• Mood & Affect: Mood is the patient's subjective emotional state (e.g., "depressed"); Affect is your objective observation of their emotional expression (e.g., flat, constricted, labile, congruent).
• Thought Process: The organization of thoughts: linear, circumstantial (over-inclusive but returns to the point), tangential (diverges and never returns), loose associations, or flight of ideas.
• Thought Content: What they are thinking about: suicidal ideation (SI), homicidal ideation (HI), delusions (fixed, false beliefs), obsessions, or compulsions.
• Perceptual Disturbances: Hallucinations (auditory are most common in psychiatric conditions; visual/tactile should prompt organic/medical evaluation) or illusions.
• Cognition & Sensorium: Orientation, concentration, memory.
• Insight & Judgment: Understanding of their illness and the ability to make sound, safe decisions.

3-Minute Oral Case Presentations

When presenting to busy preceptors on psychiatric consults or inpatient units, structure your delivery using this high-yield 3-minute framework:

1. One-Sentence Summary: Age, gender, psychiatric history, and primary reason for presentation.
2. HPI & Key Collateral: Pertinent positives and negatives from the interview, substance timeline, and historical collateral from family or electronic records.
3. Objective Findings: Physical exam, focused labs (e.g., toxicology, thyroid panel), and the MSE findings.
4. Assessment & Differential: Your leading DSM-5-TR diagnosis with supporting clinical evidence and key differentials.
5. Plan: Pharmacologic interventions, safety/suicide risk mitigation, and disposition (outpatient vs. inpatient admission).

Psychiatric SOAP Note Example

Below is a standardized template for documenting an acute inpatient follow-up visit. Always ensure that safety, suicide/violence risk assessments, and medication monitoring parameters are clearly highlighted:

S: Patient reports feeling "a bit more settled today" but continues to hear intermittent background whispering. Denies active suicidal or homicidal intent. Reports compliance with oral medications; complains of mild morning dry mouth.

O:
- Gen: Alert, cooperative, fair hygiene, making poor eye contact.
- Psychomotor: No active tremor, no extrapyramidal symptoms (EPS), normal gait.
- Speech: Slowed, normal volume, increased latency.
- Mood: "Okay."
- Affect: Constricted, partially congruent.
- Thought Process: Linear, occasional tangentiality when discussing auditory phenomena.
- Thought Content: Denies active suicidal/homicidal ideation. Delusional themes regarding neighbors persist but are less emotionally distressing.
- Perception: Acknowledges occasional auditory hallucinations ("whispering") but denies command hallucinations.
- Insight/Judgment: Poor/Fair.
- Labs: Absolute Neutrophil Count (ANC) stable at 1,800/mcL.

A: 24-year-old male with Schizophrenia, currently stabilized on Clozapine. Showing mild improvement in psychotic symptoms; tolerating medication with predictable anticholinergic side effects.

P:
- Continue Clozapine 100 mg PO daily at bedtime.
- Monitor CBC with differential weekly (Clozapine REMS registry requirement).
- Encourage hydration for xerostomia.
- Continue inpatient milieu therapy and supportive counseling.
- Reassess suicide/violence risk daily (currently low).

Acute Agitation De-escalation & Legal Criteria

Managing an acutely agitated, aggressive, or potentially violent patient requires a systematic approach prioritizing the safety of both the patient and clinical staff:

• Verbal De-escalation: Use a calm, non-threatening tone of voice. Maintain a safe physical distance (at least two arm-lengths) and keep your hands visible. Avoid direct, sustained eye contact, which can be perceived as confrontational. Offer choices where possible (e.g., "Would you like to sit down and talk, or would you prefer a quiet room?").
• Chemical Restraints: If verbal techniques fail, escalate to pharmacotherapy. Standard options include high-potency first-generation antipsychotics (e.g., Haloperidol 5 mg IM) or second-generation antipsychotics (e.g., Olanzapine 10 mg IM), often combined with a benzodiazepine (e.g., Lorazepam 2 mg IM) to reduce extrapyramidal side effects and promote sedation.
• Physical Restraints: Used only as a last resort when the patient poses an immediate physical danger to themselves or others and less restrictive measures have failed. Requires continuous close-visual or 1-to-1 monitoring and a timely face-to-face physician or PA evaluation.

Involuntary Commitment Criteria

In California, involuntary psychiatric hospitalization is initiated via a civil commitment process, commonly referred to as a 5150 hold (72-hour hold for evaluation and treatment). To place a patient on a 5150, they must meet at least one of the three legal criteria due to a mental health disorder:

1. Danger to Self (DTS): Active suicidal ideation, intent, or plan.
2. Danger to Others (DTO): Active homicidal ideation, physical threats, or violent actions directed at others.
3. Grave Disability (GD): Inability to provide for their own basic personal needs, such as food, clothing, or shelter, as a direct result of a psychiatric illness (not due to poverty alone).

Part 2: High-Yield Clinical Conditions

This section provides standard profiles for the condition categories on the PAEA EOR blueprint. Each condition follows a rigorous clinical layout to optimize both your clinical decision-making and your test performance.

1. Mood Disorders: Bipolar I vs. Unipolar Major Depressive Disorder (MDD)

Distinguishing between Bipolar and Unipolar depression is critical. Misdiagnosing a patient with unipolar depression and initiating antidepressant monotherapy can trigger a manic episode or rapid cycling.

Bipolar I Disorder

• DSM-5-TR Criteria: Requires at least one manic episode. A manic episode is defined as a sustained abnormally elevated, irritable, or expansive mood lasting at least 1 week (or any duration if hospitalization is required), accompanied by three or more symptoms (four if mood is only irritable): Grandiosity, decreased need for sleep, pressured speech, racing thoughts, distractibility, increased goal-directed activity, and risky behaviors.
• Diagnostic Workup: Thorough clinical history, screen for substance use (UDS), check thyroid function (TSH/free T4) to rule out endocrine etiologies.
• Differential Diagnosis / Look-Alikes: Borderline Personality Disorder (characterized by rapid mood shifts in response to interpersonal stressors, rather than sustained mood episodes lasting days/weeks), ADHD, Schizoaffective Disorder.
• First-Line Pharmacotherapy: Mood stabilizers (Lithium or Valproate) or second-generation antipsychotics (e.g., Quetiapine, Aripiprazole). Avoid antidepressant monotherapy.
• Second-Line Pharmacotherapy: Combination therapy (e.g., Lithium plus an atypical antipsychotic; Lamotrigine for bipolar depression).
• Non-Pharmacologic Treatment: Psychoeducation, Cognitive Behavioral Therapy (CBT), electroconvulsive therapy (ECT) for treatment-resistant mania or severe depression.
• Monitoring Guidelines & Labs:
  • Lithium: Narrow therapeutic index. Target serum level: 0.6–1.2 mEq/L (acute mania may require up to 1.5 mEq/L). Monitor renal function (BUN/Creatinine), thyroid function tests (TSH), and electrolytes prior to initiation and every 6–12 months.
  • Valproic Acid: Target serum level: 50–125 mcg/mL. Monitor complete blood count (for thrombocytopenia) and liver function tests (LFTs).
• Red Flags: Suicidal ideation during depressive or mixed episodes; signs of lithium toxicity (coarse tremors, ataxia, vomiting, confusion).

2. Neurocognitive Disorders: Delirium vs. Dementia

Delirium is a medical emergency that must be identified and managed promptly. Use the comparison below to guide your initial clinical workup.

Delirium

• DSM-5-TR Criteria: Disturbance in attention and awareness that develops over a short period (typically hours to days), represents a change from baseline, and fluctuates in severity throughout the day. Evidence from history, physical exam, or laboratory findings indicates the disturbance is a direct physiological consequence of another medical condition, substance intoxication/withdrawal, or toxin.
• Diagnostic Workup: Complete physical and neurological exam. Order a comprehensive metabolic panel (CMP), CBC, urinalysis (UA) with culture, thyroid panel, vitamin B12, toxicology screen, blood cultures, chest X-ray, and head CT if trauma or focal neurological deficits are present.
• Differential Diagnosis / Look-Alikes: Major Neurocognitive Disorder (Dementia), acute psychotic episode, non-convulsive status epilepticus.
• First-Line Pharmacotherapy: Identify and treat the underlying medical cause. For acute agitation posing an immediate safety risk, low-dose, short-term atypical or typical antipsychotics (e.g., Haloperidol 0.5–1.0 mg PO/IM) may be used. Note: Avoid benzodiazepines unless delirium is due to alcohol or sedative withdrawal.
• Second-Line Pharmacotherapy: Dexmedetomidine (Precedex) in intensive care settings.
• Non-Pharmacologic Treatment: Reorientation strategies (clocks, calendars, familiar objects), maintaining a regular sleep-wake cycle, minimizing sensory deprivation (ensure patient has their glasses and hearing aids), and avoiding physical restraints whenever possible.
• Monitoring Guidelines & Labs: Monitor vital signs, oxygen saturation, fluid balance, and electrolyte trends.
• Red Flags: New focal neurological deficits, signs of sepsis, or respiratory depression.

3. Deep Psychopharmacology: Serotonin Syndrome vs. Neuroleptic Malignant Syndrome (NMS)

Both Serotonin Syndrome and NMS are life-threatening, drug-induced medical emergencies. You must memorize their distinct pathophysiology, clinical signs, and management strategies.

Serotonin Syndrome

• Pathophysiology: Hyperstimulation of 5-HT1A and 5-HT2 receptors in the central and peripheral nervous systems, typically resulting from a combination of serotonergic agents (e.g., SSRIs, MAOIs, TCAs, Tramadol, Linezolid, MDMA).
• Clinical Findings: Triad of cognitive/behavioral alterations (agitation, confusion, hypomania), autonomic instability (diaphoresis, tachycardia, hyperthermia, hypertension), and neuromuscular hyperactivity (bilateral, spontaneous clonus, hyperreflexia, tremor). Crucially, neuromuscular symptoms are more pronounced in the lower extremities.
• First-Line Treatment: Discontinue all serotonergic medications. Provide aggressive supportive care, including IV fluids, oxygen, and cooling blankets. Benzodiazepines (e.g., Lorazepam) are first-line for muscle relaxation and to control blood pressure and heart rate.
• Second-Line Treatment: Serotonin antagonist Cyproheptadine (initial dose 12 mg, followed by 2 mg every 2 hours if symptoms persist).
• Red Flags: Hyperthermia > 41°C (105.8°F), lactic acidosis, or rhabdomyolysis.

Neuroleptic Malignant Syndrome (NMS)

• Pathophysiology: Severe central dopamine (D2) receptor blockade, typically triggered by typical or atypical antipsychotics (e.g., Haloperidol, Fluphenazine, Olanzapine) or rapid withdrawal of dopamine agonists (e.g., Levodopa).
• Clinical Findings: Characterized by severe, generalized muscular rigidity (classically described as "lead-pipe" rigidity, which contrasts with the clonus of Serotonin Syndrome), hyperthermia (often > 40°C), autonomic instability (tachycardia, labile blood pressure, tachypnea), and altered mental status (stupor, mutism, coma).
• First-Line Treatment: Immediately discontinue the offending antipsychotic. Initiate aggressive supportive therapy with IV fluids and active cooling. Administer Benzodiazepines (e.g., Lorazepam) for moderate cases.
• Second-Line Treatment: Dopamine agonists (e.g., Bromocriptine 2.5–5 mg PO/NGT every 8 hours) and/or direct muscle relaxants (e.g., Dantrolene 1–2.5 mg/kg IV every 6 hours) to control hyperthermia and severe rigidity.
• Monitoring Guidelines & Labs: Monitor serum creatine kinase (CK) levels, which are routinely elevated ($> 10,000$ U/L) due to severe muscle breakdown. Track renal function (BUN/Creatinine) to watch for acute kidney injury secondary to rhabdomyolysis.
• Red Flags: Markedly elevated CK levels, metabolic acidosis, decreased urine output (rhabdomyolysis-induced acute tubular necrosis).

Part 3: Clinical Vignettes & EOR Practice

Review the following board-style vignettes to cement your diagnostic and therapeutic reasoning. These are designed to reflect the cognitive depth of the PAEA psychiatry End of Rotation exam.

Vignette 1: Autonomic and Neuromuscular Symptoms

A 32-year-old female with a history of Major Depressive Disorder presents to the emergency department accompanied by her partner due to acute confusion, heavy sweating, and severe muscle twitching. Her current home medication is Sertraline 150 mg PO daily. She was seen at an urgent care clinic yesterday for severe migraine headache and was prescribed Sumatriptan.

On physical examination, her temperature is 38.6°C (101.5°F), pulse is 112 bpm, and blood pressure is 152/96 mmHg. She is visibly agitated and diaphoretic. Neurological examination reveals bilateral, spontaneous ankle clonus and 4+ patellar reflexes.

What is the most appropriate initial step in the pharmacologic management of this patient's current condition?

• Option A: Administer Bromocriptine
• Option B: Administer Dantrolene
• Option C: Administer Lorazepam
• Option D: Administer Haloperidol

Correct Answer and Detailed Explanation

Correct Answer: Option C (Administer Lorazepam)

• Explanation: This patient is presenting with classic features of Serotonin Syndrome (altered mental status, autonomic hyperactivity, and neuromuscular excitability), triggered by the concurrent use of an SSRI (Sertraline) and a triptan (Sumatriptan). The first-line pharmacologic treatment for Serotonin Syndrome consists of intravenous benzodiazepines (such as Lorazepam) to control agitation, reduce neuromuscular hyperactivity (clonus/tremor), and lower blood pressure and heart rate. Supportive care (discontinuing offending agents, IV hydration, and active cooling) should also be initiated immediately.

Incorrect Options Explanation:

• Option A (Bromocriptine) is a dopamine agonist used in the management of Neuroleptic Malignant Syndrome (NMS). It is not effective for Serotonin Syndrome and could exacerbate symptoms if there is diagnostic confusion.
• Option B (Dantrolene) is a direct-acting skeletal muscle relaxant used as a second-line option in severe cases of NMS to treat hyperthermia and rigidity. It is not indicated as first-line therapy for Serotonin Syndrome.
• Option C (Haloperidol) is a first-generation antipsychotic with strong dopamine antagonist properties. It should be avoided in this patient, as it can worsen muscle rigidity and further complicate the clinical picture by increasing the risk of NMS.

Vignette 2: Metabolic Monitoring

A 28-year-old male with a history of Schizoaffective Disorder is brought to the clinic for a routine clinical follow-up. He was started on a new atypical antipsychotic medication 3 months ago after experiencing an acute psychotic relapse.

During today's visit, the patient reports a 12-pound weight gain and increased thirst. Laboratory workup reveals a fasting plasma glucose of 142 mg/dL (normal $< 100$ mg/dL) and a lipid panel showing triglycerides of 240 mg/dL (normal $< 150$ mg/dL).

Which of the following medications was most likely initiated in this patient 3 months ago?

• Option A: Olanzapine
• Option B: Aripiprazole
• Option C: Ziprasidone
• Option D: Haloperidol

Correct Answer and Detailed Explanation

Correct Answer: Option A (Olanzapine)

• Explanation: Olanzapine (along with Clozapine) carries the highest risk of metabolic side effects, including rapid weight gain, insulin resistance leading to impaired glucose tolerance (hyperglycemia/Type 2 Diabetes), and hyperlipidemia among the atypical (second-generation) antipsychotics. This patient's presentation of weight gain, hyperglycemia, and hypertriglyceridemia within 3 months of starting the medication points directly to Olanzapine.

Incorrect Options Explanation:

• Option B (Aripiprazole) is a partial D2 agonist that is metabolic-neutral and has a low risk of weight gain, hyperglycemia, and lipid abnormalities.
• Option C (Ziprasidone) is another atypical antipsychotic known for being weight-neutral and having a favorable metabolic profile, though it requires monitoring for QTc prolongation.
• Option D (Haloperidol) is a first-generation (typical) antipsychotic. While it carries a high risk of extrapyramidal symptoms (EPS) and tardive dyskinesia, it is associated with a significantly lower risk of metabolic syndrome compared to second-generation antipsychotics like Olanzapine.

Generate Custom Study Resources

You have completed your review of clinical rotation skills, high-yield mood disorders, delirium vs. dementia, and acute medication-induced syndromes.

To further prepare for your upcoming rotation assessments and the PAEA EOR, you can now trigger the creation of specialized, interactive study formats tailored directly to these clinical guidelines.